AZ aims at Pfizer, GSK with potential new PARP cancer drug

AZ thinks it can improve on Lynparza, which works by inhibiting poly (ADP-ribose) polymerase (PARP), part of the specialist DNA damage repair system that cancer cells with BRCA and similar mutations rely on to survive.